Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies

Rajaei, Elham; Haybar, Habib; Mowla, Karim; Zayeri, Zeinab Deris

doi:10.2174/1573397114666180717145745

Cited by 22 publications

(16 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of this study showed that the incidence of CAD, the number of involved vessels, and the impairment of cardiac pacemaker function were higher in patients with DM (15). Our results are in line with previous non-DM patients and in a study of a large group of patients, the patients also showed a higher prevalence of the threevessel disease among DM patients (16).…”

Section: Discussionsupporting

confidence: 91%

Effect of Von Willebrand Antigen on Mortality and Major Adverse Cardiac Events in Diabetic and Non-diabetic Patients with Anterior ST Elevated Myocardial Infarction

Seyedian

Soltani

Saki

et al. 2020

Jundishapur J Chronic Dis Care

Self Cite

View full text Add to dashboard Cite

Background: Coronary artery disease (CAD) is one of the main causes of mortality in the world. The role of Von Willebrand Factor (VWF) is very important in platelet adhesion, microcirculation, and acute stenosis and it contributes to the development of atherothrombotic processes. Objectives: We decided to evaluate the level of VWF in diabetic and non-diabetic patients as an effective factor in CAD. Methods: This study was performed on 65 patients (32 diabetic patients and 33 non-diabetic patients), who referred to an Echocardiography and Angiography Department. They were evaluated for the VWF level, blood group, and fasting blood glucose. Patients underwent echocardiography, angiography, and, if necessary, percutaneous coronary intervention (PCI) during the hospitalization. They also underwent coronary artery bypass grafting (CABG) if they needed the surgery. After 40 days, we evaluated the anterior STelevation myocardial infarction (STEMI), mortality, major adverse cardiac events (MACE), heart failure, and limb ischemia. Results: The VWF level was significantly higher in diabetic patients (P < 0.0001). Also, the increased VWF levels were significantly more frequent in diabetic patients under CABG than in non-diabetic patients under CABG (P = 0.013). There was a significant relationship between positive MACE and increased VWF levels. Conclusions: The level of VWF in diabetic patients increases cardiovascular problems. Therefore, it seems that these patients can benefit from VWF-reducing drugs. Clinical research can be promising in this field.

show abstract

Section: Discussionsupporting

confidence: 91%

Effect of Von Willebrand Antigen on Mortality and Major Adverse Cardiac Events in Diabetic and Non-diabetic Patients with Anterior ST Elevated Myocardial Infarction

Seyedian

Soltani

Saki

et al. 2020

Jundishapur J Chronic Dis Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, it may also be effective in a number of other applications, such as treating cancer, obesity, nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic syndrome [ 4 ]. Furthermore, antiaging and bone-protective effects, especially in the first stages of rheumatic arthritis (RA), have also been shown very recently [ 6 , 7 ]. Emerging evidence suggests metformin may have many other benefits, including reducing endoplasmic reticulum (ER) and oxidative stress, as well as anti-inflammatory properties [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Metformin: An Old Drug with New Applications

Zhou

Massey

Story

et al. 2018

IJMS

183

124

View full text Add to dashboard Cite

Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years. The United Kingdom Prospective Diabetic Study (UKPDS) has shown metformin to improve mortality rates in diabetes patients, and recent studies suggest metformin has additional effects in treating cancer, obesity, nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic syndrome. Metformin has also been shown to alleviate weight gain associated with antipsychotic medication. Metformin has recently been extensively studied and emerging evidence suggests metformin decreases hepatocyte triglyceride accumulation in NAFLD and prevents liver tumorigenesis. Interestingly, studies have also shown metformin reduces visceral fat, suppresses white-adipose-tissue (WAT) extracellular matrix remodeling, and inhibits obesity-induced inflammation. However, clinical evidence for using metformin to treat NAFLD, cancer, metabolic syndrome, or to prevent hepatocellular carcinoma in NAFLD patients is lacking. This review therefore addresses the potential beneficial effects of metformin on NAFLD, its role in protecting against cardiac ischemia–reperfusion (I/R) injury, atherosclerosis, glucotoxicity, and lipotoxicity induced oxidative and ER stress in pancreatic β-cell dysfunction, as well as its underlying molecular mechanisms of action.

show abstract

“…An observational study on data from a Taiwan National Health Insurance Research Database found that patients with RA and T2DM under Cyclooxygenase (COX)-2 inhibitor and metformin had lower admission rates than those on COX-2 inhibitors alone [32]. Finally, a recent review strengthened metformin's multiple benefits in RA patients not only in terms of joint involvement but also affecting other frequently associated illnesses such as cardiovascular disease and cancer [70].…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

Metformin: A Potential Therapeutic Tool for Rheumatologists

et al. 2020

View full text Add to dashboard Cite

Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes, acting via indirect activation of 5′ Adenosine Monophosphate-activated Protein Kinase (AMPK). Actually, evidence has accumulated of an intriguing anti-inflammatory activity, mainly mediated by AMPK through a variety of mechanisms such as the inhibition of cytokine-stimulated Nuclear Factor-κB (NF-κB) and the downregulation of the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathways. Moreover, AMPK plays an important role in the modulation of T lymphocytes and other pivotal cells of the innate immune system. The current understanding of these AMPK effects provides a strong rationale for metformin repurposing in the management of autoimmune and inflammatory conditions. Several studies demonstrated metformin’s beneficial effects on both animal and human rheumatologic diseases, especially on rheumatoid arthritis. Unfortunately, even though data are large and remarkable, they almost exclusively come from experimental investigations with only a few from clinical trials. The lack of support from prospective placebo-controlled trials does not allow metformin to enter the therapeutic repertoire of rheumatologists. However, a large proportion of rheumatologic patients can currently benefit from metformin, such as those with concomitant obesity and type 2 diabetes, two conditions strongly associated with rheumatoid arthritis, osteoarthritis, and gout, as well as those with diabetes secondary to steroid therapy.

show abstract

Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies

Cited by 22 publications

References 78 publications

Effect of Von Willebrand Antigen on Mortality and Major Adverse Cardiac Events in Diabetic and Non-diabetic Patients with Anterior ST Elevated Myocardial Infarction

Effect of Von Willebrand Antigen on Mortality and Major Adverse Cardiac Events in Diabetic and Non-diabetic Patients with Anterior ST Elevated Myocardial Infarction

Metformin: An Old Drug with New Applications

Metformin: A Potential Therapeutic Tool for Rheumatologists

Contact Info

Product

Resources

About